Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

NETWORK 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Neoplasms 5Vipoma 4Carcinoma, Islet Cell 4Somatostatinoma 3Neuroendocrine Tumors 3Intestinal Obstruction 3Insulinoma 3Glucagonoma 3Gastrinoma 3Carcinoma, Hepatocellular 3Thymoma 2Stomach Neoplasms 2Prostatic Neoplasms 2Neoplasm Metastasis 2Meningioma 2Diarrhea 2Carcinoma 2Carcinoid Tumor 2Adenoma, Islet Cell 2Weight Loss 1Waldenstrom Macroglobulinemia 1Vomiting 1Recurrence 1Rectal Neoplasms 1Primary Inoperable Thymoma 1Pleural Effusion 1Pheochromocytoma 1Peritoneal Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1

Interventions

Sunitinib 5pembrolizumab 4Paclitaxel 4Carboplatin 4Radiotherapy 3Cyclophosphamide 3Cisplatin 3selinexor 2lenvatinib 2Taxes 2Ramucirumab 2Octreotide 2N,1,4,4-tetramethyl-8-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4,5-dihydro-1H-pyrazolo(4,3-h)quinazoline-3-carboxamide 2Methylprednisolone 2Erlotinib Hydrochloride 2Chemoradiotherapy 2zimberelimab 1saracatinib 1regorafenib 1epacadostat 1envafolimab 1belinostat 1avelumab 1atezolizumab 1amrubicin 1alovudine 1TP protocol 1Radiofrequency Ablation 1Radiation Dose Hypofractionation 1Prednisone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Thymoma × Octreotide × Clear all
NCT00003283 2023-06-15

Octreotide With or Without Prednisone in Treating Patients With Metastatic or Recurrent Thymoma

Eastern Cooperative Oncology Group

Phase 2 Completed
38 enrolled
Thoracic

Thymoma

NCT00332969 2017-03-31

Efficacy of Octreotide Treatment in Patients With Primary Inoperable Thymoma

Novartis

Phase 2 Completed
25 enrolled
Thoracic

Disease, Neoplasms, Thymoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡